Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 5Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Plasmacytoma 1Perivascular Epithelioid Cell Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Liposarcoma 1Leukemia, Prolymphocytic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Histiocytoma, Angiomatoid Fibrous 1Granuloma, Plasma Cell 1Fibrosarcoma 1Dermatofibrosarcoma 1

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Radiation × Plasma cell × Clear all
NCT02184533 2024-05-28

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Stanford University

Phase 1 Completed
15 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Plasmacytoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡